Phase 3 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must sign a consent form before joining; if you are under 18, a parent or legal guardian must also sign, and you may need to give your own agreement depending on your age and local rules.
- You must have already taken part in one of two specific related studies (called CVAY736F12301 or CVAY736F12302) and completed the full 60-week treatment period without stopping treatment early.
- Your doctor must believe that you are likely to continue to benefit from receiving the study treatment.
Who may not be able to join:
- You are currently using certain medicines or treatments that are not allowed in this study (confirm with trial site for the specific list).
- You have an active infection — such as a viral or bacterial infection — that is serious enough to need treatment given directly into a vein or muscle, and your doctor feels this would put you at risk.
- You are planning to receive any live vaccines during the time you would be in the study.
- You are currently pregnant or breastfeeding.
- You are a woman who could potentially become pregnant and are unwilling or unable to use highly effective birth control during the study and for 6 months after stopping the study drug (or longer if other medicines you take require it).
- You are a sexually active male in the United States (or other countries where locally required) and do not agree to use barrier protection (such as a condom) during sex with a woman who could become pregnant while on the study treatment.
⚠️ Important: Always verify eligibility with the trial site directly before applying. Other eligibility rules not listed here may also apply to this trial.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of treatment-emergent Adverse events/Serious Adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.